Given our results demonstrating the role of CD8+ T cells in CD47 × PD‐L1 BisAb‐mediated tumor control, we assessed the advantage of combined CD47 and PD‐L1 blockade over anti‐PD‐L1 monotherapy. This evidence concerns the gene CD8A and neoplasm.